Slingshot members are tracking this event:

Eli Lilly (LLY) Announces Positive Top-Line Results From Long Term Study EMPA-REG OUTCOME Evaluating Jardiance in Adults With Type 2 Diabetes

Do you think this event is important to the companies below? How will it affect their stock price?

Related Companies
High Medium Low
Impact on Stocks
LLY Community voting in process

Additional Information

Additional Relevant Details "Eli Lilly and Boehringer Ingelheim announced positive top-line results from EMPA-REG OUTCOME, a long-term study evaluating Jardiance in more than 7,000 adults with type 2 diabetes at high risk of CV events. The primary endpoint was met, as Jardiance demonstrated superiority to standard of care in reduction of CV risk. Jardiance is the only glucose-lowering agent to have demonstrated CV risk reduction in a long term outcome trial.
Slingshot Insights Explained
Catalyst Date
Occurred on:
Sep 25, 2015
Related Projects Image
  • Don’t see a project related to the catalyst you care about?

Related Keywords Positive-top Line Results, Empa-reg Outcome, Type 2 Diabetes, High Risk For Cv Events, Jardiance, Glucose-lowering Agent